文献速递消化道肿瘤放疗胸部肿瘤放疗

放化疗后食管癌心脏与肺剂量是总生存的独立预测因素

Heart and lung doses are independent predictors of overall survival in esophageal cancer after chemoradiotherapy.
PubMed 文献 · Clin Transl Radiat Oncol · 2019-04-24

本研究分析2004至2016年接受调强放疗(中位剂量50.4 Gy)同步放化疗±手术的560例食管癌患者,中位随访29.3个月,5年总生存(OS)率41.7%。心脏V30>45%和平均肺剂量(MLD)>10 Gy经多因素校正后与更差生存独立相关(P<0.05),且两者也是放射性心脏和肺并发症的危险因素。

要点

  • 心脏V30>45%与MLD>10 Gy是食管癌放化疗后总生存的独立不良预测因素。
  • 心脏V30>45%者心脏并发症发生率15% vs 8.5%(P=0.046)。
  • MLD>10 Gy者肺部并发症发生率27% vs 18.8%(P=0.020)。

核心结论

  • 心脏和肺受照剂量均独立预测食管癌患者更差的总生存,且是放射性并发症的危险因素,应整体最小化心脏和肺剂量。

研究设计与样本

  • 回顾性分析2004至2016年接受调强放疗(中位剂量50.4 Gy)同步放化疗±手术的560例食管癌患者,中位随访29.3个月。

主要发现

  • 全组5年总生存率为41.7%。
  • 心脏V30>45%和平均肺剂量(MLD)>10 Gy经其他临床和剂量学因素校正后与更差生存独立相关(P<0.05)。
  • 心脏V30≤45%者心脏并发症发生率8.5%,V30>45%者为15%(P=0.046)。
  • MLD≤10 Gy者肺部并发症发生率18.8%,MLD>10 Gy者为27%(P=0.020)。
  • 发生心脏并发症者5年OS率27.6% vs 无并发症者43.2%(P=0.012);发生肺部并发症者5年OS率23.1% vs 无并发症者47.4%(P<0.001)。

关键数值与推荐

  • 心脏V30>45%和MLD>10 Gy为与更差生存独立相关的剂量学阈值(采用Contal和O'Quigley法确定)。

临床怎么用

  • 食管癌同步放化疗放疗计划设计时,应尽可能降低心脏V30和平均肺剂量,以改善生存并减少放射性心脏和肺并发症。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To analyze associations between heart and lung dose and overall survival (OS) in patients with esophageal cancer who received concurrent chemo-radiotherapy (CCRT) with or without surgery. PATIENTS AND METHODS: Patients received intensity-modulated radiation therapy (median dose 50.4 Gy) from 2004 through 2016. Cutoff points for continuous variables were calculated using the method of Contal and O'Quigley. Kaplan-Meier method with log-rank tests was used to calculate survival. OS was analyzed with both univariate and multivariable Cox models. RESULTS: In all, 560 patients were analyzed; median follow-up time was 29.3 months, and 5-year OS rate was 41.7%. Heart V30 >45% and mean lung dose (MLD) >10 Gy were found to be independently associated with worse survival after adjustment for other clinical and dosimetric factors (P < 0.05). Heart and lung doses were also found to be risk factors for radiation-induced cardiac and pulmonary complications (P < 0.05): 8.5% of patients with heart V30 ≤45% had cardiac complications vs. 15% for V30 >45% (P = 0.046); 18.8% of patients with MLD ≤10 Gy had pulmonary complications vs. 27% for MLD >10 Gy (P = 0.020). Having cardiac complications was associated with worse survival (5-year OS rates 27.6% with vs. 43.2% without, P = 0.012), and having pulmonary complications was associated with worse survival as well (5-year OS rates 23.1% with vs. 47.4% without, P < 0.001). CONCLUSION: Both heart and lung doses independently predicted worse OS in patients with esophageal cancer, even after adjustment for other clinical and dosimetric factors, and were also risk factors for radiation-induced complications. Both irradiated heart and lung doses should be minimized as a whole.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Xu C, Guo L, Liao Z, et al. Heart and lung doses are independent predictors of overall survival in esophageal cancer after chemoradiotherapy. Clin Transl Radiat Oncol. 2019. PMID: 31080898. doi:10.1016/j.ctro.2019.04.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。